This research focuses on the use of low-level laser therapy (LLLT) applied to the bone marrow (BM) to ameliorate the progression of neurodegenerative diseases, specifically Alzheimer’s disease (AD), in a mouse model. The study explores the ability of LLLT to stimulate mesenchymal stem cells (MSCs) in the BM to enhance their capacity to infiltrate the brain, clear beta-amyloid (Ab) proteins, and improve cognitive function.

Key findings and methods:

LLLT was applied to BM, which led to increased proliferation and mobilization of MSCs, suggesting potential applications in regenerative medicine and neurodegenerative diseases.

MSCs stimulated by LLLT demonstrated an increased ability to mature toward a monocyte lineage and enhance the phagocytosis of soluble Ab proteins in vitro.

In a mouse model of AD, weekly LLLT to the BM for two months resulted in improved memory and spatial learning compared to non-treated AD mice. This improvement was accompanied by a significant reduction in Ab brain burden.

The study suggests that LLLT to the BM could be a therapeutic approach for progressive stages of AD and may mediate MSC therapy for amyloidogenic brain diseases.

The research findings indicate that LLLT applied to the BM can activate immune cells and MSCs, potentially enhancing their ability to reduce amyloid burden in the brain and improve cognitive function in AD mice. This approach holds promise for the treatment of AD and other neurodegenerative diseases and could have clinical relevance for human patients in the future.

To read the article click here